Lee CH, Tsai TS, Liou HH (2008) Gabapentin activates ROMK1 channels by a protein kinase A (PKA)-dependent mechanism. Br J Pharmacol 154, 216-25 18311184

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S44-p - ROMK (rat) ▲

Modsite: RQRARLVsKEGRCNI SwissProt Entrez-Gene Orthologous residues ROMK (human): S44‑p, ROMK (mouse): S25‑p, ROMK (rat): S44‑p, ROMK iso2 (rat): S25‑p Characterization Methods used to characterize site in vivo:  mutation of modification site Relevant cell lines - cell types - tissues:  oocyte Cellular systems studied:  primary cells Species studied:  frog Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE PKACA (human) pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes gabapentin increase H-89 gabapentin inhibit treatment-induced increase KT5720 gabapentin inhibit treatment-induced increase Downstream Regulation Effect of modification (function):  activity, induced, protein conformation

S219-p - ROMK (rat) ▲

Modsite: RVANLRKsLLIGSHI SwissProt Entrez-Gene Orthologous residues ROMK (human): S219‑p, ROMK (mouse): S200‑p, ROMK (rat): S219‑p, ROMK iso2 (rat): S200‑p Characterization Methods used to characterize site in vivo:  mutation of modification site Relevant cell lines - cell types - tissues:  oocyte Cellular systems studied:  primary cells Species studied:  frog Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE PKACA (human) pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes gabapentin increase H-89 gabapentin inhibit treatment-induced increase KT5720 gabapentin inhibit treatment-induced increase Downstream Regulation Effect of modification (function):  activity, induced, protein conformation

S313-p - ROMK (rat) ▲

Modsite: ATCQVRTsYVPEEVL SwissProt Entrez-Gene Orthologous residues ROMK (human): S313‑p, ROMK (mouse): S294‑p, ROMK (rat): S313‑p, ROMK iso2 (rat): S294‑p Characterization Methods used to characterize site in vivo:  mutation of modification site Relevant cell lines - cell types - tissues:  oocyte Cellular systems studied:  primary cells Species studied:  frog Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE PKACA (human) pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes gabapentin increase H-89 gabapentin inhibit treatment-induced increase KT5720 gabapentin inhibit treatment-induced increase Downstream Regulation Effect of modification (function):  activity, induced, protein conformation